Company: NDRA
Filing Date: 2025-10-30
Form Type: 424B5
Source: 0001213900-25-103705
Chunk: 9

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-30
Form: 424B5
Chunk 9
---
 strategy,
Company entered into a Master Custody Service Agreement with Anchorage (the “Custody Agreement”), pursuant to which it will
act as custodian of the Company’s digital assets it deposits with Anchorage. Services provided by Anchorage will include storage
of digital assets and related settlement and support services. Under the Custody Agreement, Anchorage does not have the authority to assign,
hypothecate, pledge, encumber or otherwise dispose of our digital assets, subject to a lien to secure payment to Anchorage in respect
of its services. The Custody Agreement has an initial term of one year, at which time it will automatically renew for successive renewal
terms unless either party provides no less than 30 days’ prior written notice.

TAEUS Technology Platform

Currently, we are developing a next-generation
enhanced ultrasound technology platform-Thermo-Acoustic Enhanced Ultrasound, or TAEUS. Our first TAEUS platform application
focuses on measuring fat in the liver.

TAEUS technology uses a pulsed energy source--specifically,
radio frequency (“RF”)--to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition
(or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface
and used to create high-contrast images (and other forms of data) using our proprietary algorithms. Unlike conventional ultrasound, which
creates images based on the scattering properties of tissue structure, thermoacoustic imaging provides tissue absorption maps that differentiate
lean and fatty tissues. Acoustic waves (ultrasound) are only utilized to transmit the absorption signal to the imaging system outside
of the body.

To increase the versatility of our thermoacoustic
technology, we developed TAEUS technology as a platform for multiple applications. Unlike the near-infrared light pulses used in our earlier
photoacoustic systems, our TAEUS technology uses RF pulses to stimulate tissues, using a small fraction of the energy that is typically
transmitted into the body during an MRI scan. Using RF energy enables TAEUS technology to penetrate deep into tissue, enabling tissue
composition at clinically relevant depths. The RF pulses are absorbed by tissue and converted into ultrasound signals, which are detected
by an external ultrasound receiver and a digital acquisition system that is part of the TAEUS system. The detected ultrasound can then
be processed into ultrasound overlays or quantitative data that may be translated into clinically useful metrics using our proprietary
algorithms and displayed to complement conventional gray